NASDAQ:MIST Milestone Pharmaceuticals (MIST) Stock Price, News & Analysis $1.43 -0.02 (-1.38%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.46 +0.03 (+1.75%) As of 08/1/2025 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Milestone Pharmaceuticals Stock (NASDAQ:MIST) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MIST alerts:Sign Up Key Stats Today's Range$1.40▼$1.4850-Day Range$1.38▼$2.5652-Week Range$0.63▼$2.75Volume671,601 shsAverage Volume2.82 million shsMarket Capitalization$76.45 millionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingHold Company Overview Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada. Read More Milestone Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScoreMIST MarketRank™: Milestone Pharmaceuticals scored higher than 36% of companies evaluated by MarketBeat, and ranked 709th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingMilestone Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageMilestone Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Milestone Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Milestone Pharmaceuticals are expected to decrease in the coming year, from ($0.62) to ($1.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Milestone Pharmaceuticals is -1.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Milestone Pharmaceuticals is -1.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMilestone Pharmaceuticals has a P/B Ratio of 5.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Milestone Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.58% of the outstanding shares of Milestone Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverMilestone Pharmaceuticals has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Milestone Pharmaceuticals has recently increased by 159.90%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMilestone Pharmaceuticals does not currently pay a dividend.Dividend GrowthMilestone Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.58% of the outstanding shares of Milestone Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverMilestone Pharmaceuticals has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Milestone Pharmaceuticals has recently increased by 159.90%, indicating that investor sentiment is decreasing significantly. News and Social Media1.7 / 5News SentimentN/A News SentimentMilestone Pharmaceuticals has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Milestone Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest7 people have searched for MIST on MarketBeat in the last 30 days. MarketBeat Follows7 people have added Milestone Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Milestone Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders19.50% of the stock of Milestone Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.18% of the stock of Milestone Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Milestone Pharmaceuticals' insider trading history. Receive MIST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Milestone Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address MIST Stock News HeadlinesAnalysts Offer Insights on Healthcare Companies: Kestra Medical Technologies Ltd. (KMTS) and Milestone Pharmaceuticals (MIST)July 18, 2025 | theglobeandmail.comMilestone Pharmaceuticals Remains A Buying Opportunity Despite Recent DilutionJuly 18, 2025 | seekingalpha.comIs America’s Everything Bubble About to Burst?On July 4th, Trump signed the “One Big Beautiful Bill,” adding $3.4 trillion to the national debt — and pushing America’s debt-to-GDP ratio to 175%. Top investors are warning of an epic bubble bursting soon. A free guide reveals how to shield your 401(k), savings, and portfolio before the collapse. | American Alternative (Ad)Milestone Pharmaceuticals Announces Public Offering for $48.7MJuly 16, 2025 | theglobeandmail.comTD Cowen Sticks to Its Hold Rating for Milestone Pharmaceuticals (MIST)July 16, 2025 | theglobeandmail.comMilestone Pharmaceuticals Inc. (MIST) Stock Price Today - WSJJuly 11, 2025 | wsj.comMilestone says heart disorder therapy under FDA review againJuly 11, 2025 | msn.comMilestone Pharmaceuticals stock plunges on public offering announcementJuly 11, 2025 | au.investing.comSee More Headlines MIST Stock Analysis - Frequently Asked Questions How have MIST shares performed this year? Milestone Pharmaceuticals' stock was trading at $2.36 on January 1st, 2025. Since then, MIST shares have decreased by 39.4% and is now trading at $1.43. How were Milestone Pharmaceuticals' earnings last quarter? Milestone Pharmaceuticals Inc. (NASDAQ:MIST) issued its earnings results on Wednesday, May, 14th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.12. When did Milestone Pharmaceuticals IPO? Milestone Pharmaceuticals (MIST) raised $75 million in an IPO on Thursday, May 9th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Cowen and Piper Jaffray served as the underwriters for the IPO and Oppenheimer & Co. was co-manager. Who are Milestone Pharmaceuticals' major shareholders? Top institutional shareholders of Milestone Pharmaceuticals include Valeo Financial Advisors LLC (0.24%) and Bay Rivers Group (0.03%). Insiders that own company stock include Rtw Investments, Lp, Robert James Wills, David Bharucha and Debra K Liebert. View institutional ownership trends. How do I buy shares of Milestone Pharmaceuticals? Shares of MIST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Milestone Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Milestone Pharmaceuticals investors own include OPKO Health (OPK), Corbus Pharmaceuticals (CRBP), Tilray Brands (TLRY), VBI Vaccines (VBIV), CymaBay Therapeutics (CBAY), Vaxart (VXRT) and Aquestive Therapeutics (AQST). Company Calendar Last Earnings5/14/2025Today8/02/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MIST CIK1408443 Webwww.milestonepharma.com Phone(514) 336-0444FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Price Target for Milestone Pharmaceuticals$7.00 High Price Target$9.00 Low Price Target$5.00 Potential Upside/Downside+389.5%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$41.52 million Net MarginsN/A Pretax MarginN/A Return on Equity-329.85% Return on Assets-67.20% Debt Debt-to-Equity Ratio4.06 Current Ratio4.67 Quick Ratio4.67 Sales & Book Value Annual Sales$1 million Price / Sales76.45 Cash FlowN/A Price / Cash FlowN/A Book Value$0.25 per share Price / Book5.72Miscellaneous Outstanding Shares53,460,000Free Float43,039,000Market Cap$76.45 million OptionableOptionable Beta0.52 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:MIST) was last updated on 8/3/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredInvestigating the Most Controversial Stock on EarthTesla’s wild price swings may not be random after all. Hedge fund veteran Larry Benedict has uncovered a st...Brownstone Research | SponsoredThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredSell these "safe" blue chips immediatelyInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Milestone Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Milestone Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.